Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

169 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase II study of afatinib, an irreversible ErbB family blocker, added to letrozole in patients with estrogen receptor-positive hormone-refractory metastatic breast cancer progressing on letrozole.
Gunzer K, Joly F, Ferrero JM, Gligorov J, de Mont-Serrat H, Uttenreuther-Fischer M, Pelling K, Wind S, Bousquet G, Misset JL. Gunzer K, et al. Among authors: bousquet g. Springerplus. 2016 Jan 19;5:45. doi: 10.1186/s40064-015-1601-7. eCollection 2016. Springerplus. 2016. PMID: 26835225 Free PMC article.
A Minimal PBPK Model for Plasma and Cerebrospinal Fluid Pharmacokinetics of Trastuzumab after Intracerebroventricular Administration in Patients with HER2-Positive Brain Metastatic Localizations.
Puszkiel A, Bousquet G, Stanke-Labesque F, Stocco J, Decq P, Chevillard L, Goutagny S, Declèves X. Puszkiel A, et al. Among authors: bousquet g. Pharm Res. 2023 Nov;40(11):2687-2697. doi: 10.1007/s11095-023-03614-w. Epub 2023 Oct 11. Pharm Res. 2023. PMID: 37821769
Metastatic clear-cell renal cell carcinoma: a frequent NOTCH1 mutation predictive of response to anti-NOTCH1 CB-103 treatment.
Bui TO, Angeli E, El Bouchtaoui M, Gapihan G, Dao VT, Paris J, Leboeuf C, Soussan M, Villarese P, Ziol M, Van Glabeke E, Le TH, Feugeas JP, Janin A, Bousquet G. Bui TO, et al. Among authors: bousquet g. Exp Hematol Oncol. 2023 May 15;12(1):46. doi: 10.1186/s40164-023-00408-z. Exp Hematol Oncol. 2023. PMID: 37189165 Free PMC article.
[Lung cancers in the elderly].
Trédaniel J, Savinelli F, Sergent G, Bousquet G, Le Maignan C, Hennequin C, Gossot D, Misset JL. Trédaniel J, et al. Among authors: bousquet g. Bull Cancer. 2008 May 28;95 FMC Onco:F57-64. doi: 10.1684/bdc.2007.0536. Bull Cancer. 2008. PMID: 18511368 French.
Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.
Gravis G, Fizazi K, Joly F, Oudard S, Priou F, Esterni B, Latorzeff I, Delva R, Krakowski I, Laguerre B, Rolland F, Théodore C, Deplanque G, Ferrero JM, Pouessel D, Mourey L, Beuzeboc P, Zanetta S, Habibian M, Berdah JF, Dauba J, Baciuchka M, Platini C, Linassier C, Labourey JL, Machiels JP, El Kouri C, Ravaud A, Suc E, Eymard JC, Hasbini A, Bousquet G, Soulie M. Gravis G, et al. Among authors: bousquet g. Lancet Oncol. 2013 Feb;14(2):149-58. doi: 10.1016/S1470-2045(12)70560-0. Epub 2013 Jan 8. Lancet Oncol. 2013. PMID: 23306100 Clinical Trial.
6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial.
Pivot X, Romieu G, Debled M, Pierga JY, Kerbrat P, Bachelot T, Lortholary A, Espié M, Fumoleau P, Serin D, Jacquin JP, Jouannaud C, Rios M, Abadie-Lacourtoisie S, Tubiana-Mathieu N, Cany L, Catala S, Khayat D, Pauporté I, Kramar A; PHARE trial investigators. Pivot X, et al. Lancet Oncol. 2013 Jul;14(8):741-8. doi: 10.1016/S1470-2045(13)70225-0. Epub 2013 Jun 11. Lancet Oncol. 2013. PMID: 23764181 Clinical Trial.
Patients' self-assessment versus investigators' evaluation in a phase III trial in non-castrate metastatic prostate cancer (GETUG-AFU 15).
Gravis G, Marino P, Joly F, Oudard S, Priou F, Esterni B, Latorzeff I, Delva R, Krakowski I, Laguerre B, Rolland F, Théodore C, Deplanque G, Ferrero JM, Pouessel D, Mourey L, Beuzeboc P, Zanetta S, Habibian M, Berdah JF, Dauba J, Baciuchka M, Platini C, Linassier C, Labourey JL, Machiels JP, El Kouri C, Ravaud A, Suc E, Eymard JC, Hasbini A, Bousquet G, Soulie M, Fizazi K. Gravis G, et al. Among authors: bousquet g. Eur J Cancer. 2014 Mar;50(5):953-62. doi: 10.1016/j.ejca.2013.11.034. Epub 2014 Jan 11. Eur J Cancer. 2014. PMID: 24424105 Clinical Trial.
169 results